🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 179 (from laksa026)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa179.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound\')), getAhrefsUnparsedNoserviceFromURL(\'https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound","crawl_time":1775842328,"first_indexed_time":1708504886,"http_code":200,"src_unparsed":"edu,jhu!publichealth,\/2024\/what-to-know-about-covid-rebound s443","src_root_hash":"6599457417117746179","history_drop_reason":null,"meta_title":"What to Know About COVID Rebound | Johns Hopkins | Bloomberg School of Public Health","meta_descriptions":["Some people recover from COVID only to have their symptoms return a few days later. That doesn’t surprise virologists."],"attrs_boilerpipe_text":"What initially was referred to as “Paxlovid rebound”—a return of COVID symptoms or test positivity after starting a course of the antiviral—is now more accurately referred to as “COVID rebound,” because rebound can happen regardless of whether someone takes antivirals.\nWhat’s more,\nit’s likely not a phenomenon unique to COVID, says\nvirologist\nAndy Pekosz\n, PhD, a professor in\nMolecular Microbiology and Immunology\n. What\nis\nunique to COVID is the technology—specifically rapid antigen tests—that allows us to track the progress of an infection so closely.\nResearchers are continuing to investigate why some people experience COVID rebound, whether people are contagious during this period, and the role antivirals like Paxlovid might play. But one thing is certain, says\nAmesh Adalja\n, MD,\na senior scholar at the\nJohns Hopkins Center for Health Security\n(link is external)\nwho specializes in infectious diseases and pandemic preparedness: The possibility that someone might experience mild rebound symptoms should not deter them from taking Paxlovid if they are at a higher risk for severe illness.\nWhat is COVID rebound?\nCOVID rebound is “typically described as a recurrence of signs or symptoms or a new positive viral test result after initial recovery from COVID-19,”\naccording to the CDC\n(link is external)\n. The order of events generally looks like this: A person is infected with and has symptoms of COVID; their symptoms subside over the course of the infection, and they test negative for COVID on a home antigen test; their symptoms return, and they may test positive again on a home antigen test.\nRebound symptoms are generally mild, and no hospitalizations or deaths have occurred as a result of rebound, according to a\nDecember 2023 CDC report\n(link is external)\n.\nWhy do some people experience COVID rebound? \nResearchers are still working to understand why rebound happens and how it varies from person to person—with some experiencing a return of symptoms and others only seeing evidence through antigen testing. But at a molecular level, the fact that rebound occurs is not surprising, says Andy Pekosz.\n“We think about an infection as starting as nothing, going up to a peak, and then going away, but in reality, your body is much more complicated than that,” he says. Using more sensitive tools, virologists have seen that the amount of virus present in someone with COVID goes up and down over the course of an infection, causing different degrees of symptoms.\nDoes Paxlovid cause rebound symptoms?\nA CDC review of COVID rebound studies\n(link is external)\nfound “no consistent association between treatment and rebound.” Paxlovid does not directly\ncause\nsymptoms to return; in fact, only about\n1 in 5 people who take Paxlovid experience rebound\n(link is external)\n, and many of those are asymptomatic.\n“Paxlovid is taken daily for five days, and it’s possible that the immune response is somewhat blunted during that period. The hypothesis is that after those five days, the drug pressure from Paxlovid is gone and whatever remnants of the virus are still present are able to cause symptoms again,” Adalja says. “We don’t quite understand why it happens in some people and not others, but it likely has to do with the nuance of the immune response and how that's impacted by antivirals.”\nThe risk of rebound\nshould not preclude someone who's at high risk or severe disease from taking Paxlovid\n, and it definitely shouldn’t preclude doctors from prescribing it. “Taking Paxlovid clearly reduces the likelihood of an individual developing severe COVID, irrespective of COVID rebound,” Pekosz emphasizes.\nCan COVID rebound happen to people who don’t take Paxlovid?\nYes. In fall 2020 and spring 2021—before Paxlovid became available—Pekosz and other virologists studied\nhow infectiousness and viral load varied among individuals\n(link is external)\nover the course of a COVID infection. Their results showed\nnumerous instances of what we now describe as COVID rebound\n(link is external)\n: a return of symptoms or positive antigen test.\nThese results weren’t unexpected, according to Pekosz. “Many of us virologists assumed [rebound] was happening because we understand that these viruses come and go, they're not smooth curves in terms of your responses,” he says.\nIs a person contagious while they have rebound symptoms?\nPossibly—but Adalja explains that contagiousness is better determined by test positivity than symptoms. “If a person experiences rebound symptoms but doesn’t test positive on a home antigen test, they likely aren’t shedding enough virus to be infectious,” he says. “However, if they test positive on a home antigen test, that does likely correlate with contagiousness.”\nWhen someone tests positive on a home antigen test, does the darkness of the test line correlate to contagiousness?\nA faint line on a home antigen test is still a positive test result. “The tests are validated to tell you yes or no” to whether it detects viral material, Pekosz explains, not how contagious you are. “A dark line does mean more viral load,” he says, but there’s no system that correlates different shades of red with level of contagiousness.\n“If you're testing positive following a previous negative test or following a full course of Paxlovid, that's where masking and distancing becomes important,” Pekosz says. “But again, only at the tail end of an infection, when you’re feeling better and symptoms aren’t severe.”\nDoes rebound happen with other viruses, like flu and RSV?\nIt’s likely that rebound occurs with other viral infections, Pekosz explains. “It probably happens with influenza, but we don't have the at-home tests to capture that,” Pekosz says, adding that he hopes future availability of at-home flu tests will allow virologists to analyze flu cases like they have with COVID.\n“What we can do in terms of diagnosing ourselves with COVID and following the course of the disease is light-years ahead of what we can do for influenza,” Pekosz says. “It’s a testament to the fact that we've done good science and gotten these tools in place to see these kinds of variations that we've never been able to see with other viruses or infections.”\nAliza Rosen is a digital content strategist in the Office of External Affairs at the Johns Hopkins Bloomberg School of Public Health.\nRELATED:\nMore Americans Could Benefit from Paxlovid for COVID Infection\nWhat to Know About JN.1, the Latest Omicron Variant","attrs_markdown":"[Johns Hopkins UniversityEst. 1876 America’s First Research University](https:\/\/150.jhu.edu\/)\n\n[Skip to main content](https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound#main-content)\n\n- [Expand](https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound) [Departments](https:\/\/publichealth.jhu.edu\/departments)\n  - [Biochemistry and Molecular Biology](https:\/\/publichealth.jhu.edu\/departments\/biochemistry-and-molecular-biology)\n  - [Biostatistics](https:\/\/publichealth.jhu.edu\/departments\/biostatistics)\n  - [Environmental Health and Engineering](https:\/\/publichealth.jhu.edu\/departments\/environmental-health-and-engineering)\n  - [Epidemiology](https:\/\/publichealth.jhu.edu\/departments\/epidemiology)\n  - [Health Policy and Management](https:\/\/publichealth.jhu.edu\/departments\/health-policy-and-management)\n  - [Health, Behavior and Society](https:\/\/publichealth.jhu.edu\/departments\/health-behavior-and-society)\n  - [International Health](https:\/\/publichealth.jhu.edu\/departments\/international-health)\n  - [Mental Health](https:\/\/publichealth.jhu.edu\/departments\/mental-health)\n  - [Molecular Microbiology and Immunology](https:\/\/publichealth.jhu.edu\/departments\/molecular-microbiology-and-immunology)\n  - [Population, Family and Reproductive Health](https:\/\/publichealth.jhu.edu\/departments\/population-family-and-reproductive-health)\n- [Faculty](https:\/\/publichealth.jhu.edu\/faculty\/directory\/list)\n- [Topics](https:\/\/publichealth.jhu.edu\/topics)\n\n- [Departments »](https:\/\/publichealth.jhu.edu\/departments)\n  - [Biochemistry and Molecular Biology](https:\/\/publichealth.jhu.edu\/departments\/biochemistry-and-molecular-biology)\n  - [Biostatistics](https:\/\/publichealth.jhu.edu\/departments\/biostatistics)\n  - [Environmental Health and Engineering](https:\/\/publichealth.jhu.edu\/departments\/environmental-health-and-engineering)\n  - [Epidemiology](https:\/\/publichealth.jhu.edu\/departments\/epidemiology)\n  - [Health Policy and Management](https:\/\/publichealth.jhu.edu\/departments\/health-policy-and-management)\n  - [Health, Behavior and Society](https:\/\/publichealth.jhu.edu\/departments\/health-behavior-and-society)\n  - [International Health](https:\/\/publichealth.jhu.edu\/departments\/international-health)\n  - [Mental Health](https:\/\/publichealth.jhu.edu\/departments\/mental-health)\n  - [Molecular Microbiology and Immunology](https:\/\/publichealth.jhu.edu\/departments\/molecular-microbiology-and-immunology)\n  - [Population, Family and Reproductive Health](https:\/\/publichealth.jhu.edu\/departments\/population-family-and-reproductive-health)\n- [Faculty](https:\/\/publichealth.jhu.edu\/faculty\/directory\/list)\n- [Topics](https:\/\/publichealth.jhu.edu\/topics)\n\nSearch\n\n[![Home](https:\/\/publichealth.jhu.edu\/themes\/custom\/jhsph\/images\/logo.svg)](https:\/\/publichealth.jhu.edu\/)\n\nToggle menus\n\n- [Expand](https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound) [Academics](https:\/\/publichealth.jhu.edu\/academics)\n  - [Explore Programs](https:\/\/publichealth.jhu.edu\/academics\/explore-programs)\n  - [Admissions Services](https:\/\/publichealth.jhu.edu\/offices-and-services\/office-of-admissions-services \"Admissions Services\")\n  - [Course Directory](https:\/\/publichealth.jhu.edu\/courses)\n  - [Academic Calendar](https:\/\/publichealth.jhu.edu\/academics\/academic-calendar)\n  - [Lecture Series](https:\/\/publichealth.jhu.edu\/academics\/lecture-series)\n  - [Convocation](https:\/\/publichealth.jhu.edu\/academics\/convocation)\n- [Expand](https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound) [Research](https:\/\/publichealth.jhu.edu\/researchbsph)\n  - [Strategy and Development](https:\/\/publichealth.jhu.edu\/researchbsph\/strategy-and-development)\n  - [Implementation and Impact](https:\/\/publichealth.jhu.edu\/researchbsph\/implementation-and-impact)\n  - [Integrity and Oversight](https:\/\/publichealth.jhu.edu\/researchbsph\/integrity-and-oversight)\n- [Expand](https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound) [Practice](https:\/\/publichealth.jhu.edu\/practice)\n  - [In the School](https:\/\/publichealth.jhu.edu\/practice\/in-the-school)\n  - [In the Field](https:\/\/publichealth.jhu.edu\/practice\/in-the-field)\n  - [In Baltimore](https:\/\/publichealth.jhu.edu\/practice\/in-baltimore)\n  - [Resources for Practitioners](https:\/\/publichealth.jhu.edu\/practice\/resources-for-practitioners)\n- [Expand](https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound) [Headlines](https:\/\/publichealth.jhu.edu\/headlines)\n  - [Articles & News Releases](https:\/\/publichealth.jhu.edu\/headlines\/articles-news-releases)\n  - [In The News](https:\/\/publichealth.jhu.edu\/headlines\/in-the-news)\n  - [Newsletter](https:\/\/publichealth.jhu.edu\/headlines\/public-health-insights-newsletter)\n  - [Podcast](https:\/\/publichealth.jhu.edu\/headlines\/public-health-on-call-podcast)\n  - [Magazine](https:\/\/magazine.publichealth.jhu.edu\/)\n  - [Events](https:\/\/publichealth.jhu.edu\/events)\n  - [Statements & Announcements](https:\/\/publichealth.jhu.edu\/headlines\/statements-announcements)\n  - [Newsroom](https:\/\/publichealth.jhu.edu\/headlines\/newsroom)\n- [Expand](https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound) [About](https:\/\/publichealth.jhu.edu\/about)\n  - [At a Glance](https:\/\/publichealth.jhu.edu\/about\/at-a-glance)\n  - [Leadership](https:\/\/publichealth.jhu.edu\/about\/leadership)\n  - [Student Life](https:\/\/publichealth.jhu.edu\/about\/student-life)\n  - [Campus](https:\/\/publichealth.jhu.edu\/about\/our-campus)\n  - [Baltimore](https:\/\/publichealth.jhu.edu\/about\/our-home-city-of-baltimore)\n  - [Inclusion, Diversity, Anti-Racism, and Equity (IDARE)](https:\/\/publichealth.jhu.edu\/about\/inclusion-diversity-anti-racism-and-equity-idare)\n  - [History](https:\/\/publichealth.jhu.edu\/about\/history)\n  - [What is Public Health?](https:\/\/publichealth.jhu.edu\/about\/what-is-public-health)\n- [Apply](https:\/\/publichealth.jhu.edu\/offices-and-services\/office-of-admissions-services\/how-to-apply)\n\n- [Academics](https:\/\/publichealth.jhu.edu\/academics)\n  - [Explore Programs](https:\/\/publichealth.jhu.edu\/academics\/explore-programs)\n  - [Admissions Services](https:\/\/publichealth.jhu.edu\/offices-and-services\/office-of-admissions-services \"Admissions Services\")\n  - [Course Directory](https:\/\/publichealth.jhu.edu\/courses)\n  - [Academic Calendar](https:\/\/publichealth.jhu.edu\/academics\/academic-calendar)\n  - [Lecture Series](https:\/\/publichealth.jhu.edu\/academics\/lecture-series)\n  - [Convocation](https:\/\/publichealth.jhu.edu\/academics\/convocation)\n- [Research](https:\/\/publichealth.jhu.edu\/researchbsph)\n  - [Strategy and Development](https:\/\/publichealth.jhu.edu\/researchbsph\/strategy-and-development)\n  - [Implementation and Impact](https:\/\/publichealth.jhu.edu\/researchbsph\/implementation-and-impact)\n  - [Integrity and Oversight](https:\/\/publichealth.jhu.edu\/researchbsph\/integrity-and-oversight)\n- [Practice](https:\/\/publichealth.jhu.edu\/practice)\n  - [In the School](https:\/\/publichealth.jhu.edu\/practice\/in-the-school)\n  - [In the Field](https:\/\/publichealth.jhu.edu\/practice\/in-the-field)\n  - [In Baltimore](https:\/\/publichealth.jhu.edu\/practice\/in-baltimore)\n  - [Resources for Practitioners](https:\/\/publichealth.jhu.edu\/practice\/resources-for-practitioners)\n- [Headlines](https:\/\/publichealth.jhu.edu\/headlines)\n  - [Articles & News Releases](https:\/\/publichealth.jhu.edu\/headlines\/articles-news-releases)\n  - [In The News](https:\/\/publichealth.jhu.edu\/headlines\/in-the-news)\n  - [Newsletter](https:\/\/publichealth.jhu.edu\/headlines\/public-health-insights-newsletter)\n  - [Podcast](https:\/\/publichealth.jhu.edu\/headlines\/public-health-on-call-podcast)\n  - [Magazine](https:\/\/magazine.publichealth.jhu.edu\/)\n  - [Events](https:\/\/publichealth.jhu.edu\/events)\n  - [Statements & Announcements](https:\/\/publichealth.jhu.edu\/headlines\/statements-announcements)\n  - [Newsroom](https:\/\/publichealth.jhu.edu\/headlines\/newsroom)\n- [About](https:\/\/publichealth.jhu.edu\/about)\n  - [At a Glance](https:\/\/publichealth.jhu.edu\/about\/at-a-glance)\n  - [Leadership](https:\/\/publichealth.jhu.edu\/about\/leadership)\n  - [Student Life](https:\/\/publichealth.jhu.edu\/about\/student-life)\n  - [Campus](https:\/\/publichealth.jhu.edu\/about\/our-campus)\n  - [Baltimore](https:\/\/publichealth.jhu.edu\/about\/our-home-city-of-baltimore)\n  - [Inclusion, Diversity, Anti-Racism, and Equity (IDARE)](https:\/\/publichealth.jhu.edu\/about\/inclusion-diversity-anti-racism-and-equity-idare)\n  - [History](https:\/\/publichealth.jhu.edu\/about\/history)\n  - [What is Public Health?](https:\/\/publichealth.jhu.edu\/about\/what-is-public-health)\n- [Apply](https:\/\/publichealth.jhu.edu\/offices-and-services\/office-of-admissions-services\/how-to-apply)\n\n- [Expand](https:\/\/publichealth.jhu.edu\/2024\/what-to-know-about-covid-rebound) [Departments](https:\/\/publichealth.jhu.edu\/departments)\n  - [Biochemistry and Molecular Biology](https:\/\/publichealth.jhu.edu\/departments\/biochemistry-and-molecular-biology)\n  - [Biostatistics](https:\/\/publichealth.jhu.edu\/departments\/biostatistics)\n  - [Environmental Health and Engineering](https:\/\/publichealth.jhu.edu\/departments\/environmental-health-and-engineering)\n  - [Epidemiology](https:\/\/publichealth.jhu.edu\/departments\/epidemiology)\n  - [Health Policy and Management](https:\/\/publichealth.jhu.edu\/departments\/health-policy-and-management)\n  - [Health, Behavior and Society](https:\/\/publichealth.jhu.edu\/departments\/health-behavior-and-society)\n  - [International Health](https:\/\/publichealth.jhu.edu\/departments\/international-health)\n  - [Mental Health](https:\/\/publichealth.jhu.edu\/departments\/mental-health)\n  - [Molecular Microbiology and Immunology](https:\/\/publichealth.jhu.edu\/departments\/molecular-microbiology-and-immunology)\n  - [Population, Family and Reproductive Health](https:\/\/publichealth.jhu.edu\/departments\/population-family-and-reproductive-health)\n- [Faculty](https:\/\/publichealth.jhu.edu\/faculty\/directory\/list)\n- [Topics](https:\/\/publichealth.jhu.edu\/topics)\n\n- [Departments »](https:\/\/publichealth.jhu.edu\/departments)\n  - [Biochemistry and Molecular Biology](https:\/\/publichealth.jhu.edu\/departments\/biochemistry-and-molecular-biology)\n  - [Biostatistics](https:\/\/publichealth.jhu.edu\/departments\/biostatistics)\n  - [Environmental Health and Engineering](https:\/\/publichealth.jhu.edu\/departments\/environmental-health-and-engineering)\n  - [Epidemiology](https:\/\/publichealth.jhu.edu\/departments\/epidemiology)\n  - [Health Policy and Management](https:\/\/publichealth.jhu.edu\/departments\/health-policy-and-management)\n  - [Health, Behavior and Society](https:\/\/publichealth.jhu.edu\/departments\/health-behavior-and-society)\n  - [International Health](https:\/\/publichealth.jhu.edu\/departments\/international-health)\n  - [Mental Health](https:\/\/publichealth.jhu.edu\/departments\/mental-health)\n  - [Molecular Microbiology and Immunology](https:\/\/publichealth.jhu.edu\/departments\/molecular-microbiology-and-immunology)\n  - [Population, Family and Reproductive Health](https:\/\/publichealth.jhu.edu\/departments\/population-family-and-reproductive-health)\n- [Faculty](https:\/\/publichealth.jhu.edu\/faculty\/directory\/list)\n- [Topics](https:\/\/publichealth.jhu.edu\/topics)\n\nSearch\n\nBloomberg School\n\n# COVID Rebound Can Happen Whether or Not You Take Paxlovid\nHow our bodies respond to viral infections is “not a smooth curve”\n\nPublished\n\nFebruary 20, 2024\n\nBy\n\nAliza Rosen\n\n[COVID-19](https:\/\/publichealth.jhu.edu\/topics\/covid-19-and-public-health)\n\n[Drugs](https:\/\/publichealth.jhu.edu\/topics\/drugs-and-public-health)\n\n[Infectious Diseases](https:\/\/publichealth.jhu.edu\/topics\/infectious-diseases-and-public-health)\n\n![A woman sits on a couch wrapped in a blanket blowing her nose ](https:\/\/publichealth.jhu.edu\/sites\/default\/files\/styles\/article_feature\/public\/2024-02\/covid-rebound-symptoms.jpg?h=6e972868&itok=vRxA1UF7)\n\nWhat initially was referred to as “Paxlovid rebound”—a return of COVID symptoms or test positivity after starting a course of the antiviral—is now more accurately referred to as “COVID rebound,” because rebound can happen regardless of whether someone takes antivirals.\n\nWhat’s more, it’s likely not a phenomenon unique to COVID, says virologist [Andy Pekosz](https:\/\/publichealth.jhu.edu\/faculty\/1972\/andrew-stanley-pekosz), PhD, a professor in [Molecular Microbiology and Immunology](https:\/\/publichealth.jhu.edu\/departments\/molecular-microbiology-and-immunology). What *is* unique to COVID is the technology—specifically rapid antigen tests—that allows us to track the progress of an infection so closely.\n\nResearchers are continuing to investigate why some people experience COVID rebound, whether people are contagious during this period, and the role antivirals like Paxlovid might play. But one thing is certain, says [Amesh Adalja](https:\/\/publichealth.jhu.edu\/faculty\/3528\/amesh-adalja), MD, a senior scholar at the [Johns Hopkins Center for Health Security](https:\/\/www.centerforhealthsecurity.org\/ \"(opens in a new window)\") who specializes in infectious diseases and pandemic preparedness: The possibility that someone might experience mild rebound symptoms should not deter them from taking Paxlovid if they are at a higher risk for severe illness.\n\n##### **What is COVID rebound?**\nCOVID rebound is “typically described as a recurrence of signs or symptoms or a new positive viral test result after initial recovery from COVID-19,” [according to the CDC](https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7251a1.htm \"(opens in a new window)\"). The order of events generally looks like this: A person is infected with and has symptoms of COVID; their symptoms subside over the course of the infection, and they test negative for COVID on a home antigen test; their symptoms return, and they may test positive again on a home antigen test.\n\nRebound symptoms are generally mild, and no hospitalizations or deaths have occurred as a result of rebound, according to a [December 2023 CDC report](https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7251a1.htm \"(opens in a new window)\").\n\n##### **Why do some people experience COVID rebound?**\nResearchers are still working to understand why rebound happens and how it varies from person to person—with some experiencing a return of symptoms and others only seeing evidence through antigen testing. But at a molecular level, the fact that rebound occurs is not surprising, says Andy Pekosz.\n\n“We think about an infection as starting as nothing, going up to a peak, and then going away, but in reality, your body is much more complicated than that,” he says. Using more sensitive tools, virologists have seen that the amount of virus present in someone with COVID goes up and down over the course of an infection, causing different degrees of symptoms.\n\n##### **Does Paxlovid cause rebound symptoms?**\n[A CDC review of COVID rebound studies](https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7251a1.htm \"(opens in a new window)\") found “no consistent association between treatment and rebound.” Paxlovid does not directly *cause* symptoms to return; in fact, only about [1 in 5 people who take Paxlovid experience rebound](https:\/\/www.acpjournals.org\/doi\/10.7326\/M23-1756 \"(opens in a new window)\"), and many of those are asymptomatic.\n\n“Paxlovid is taken daily for five days, and it’s possible that the immune response is somewhat blunted during that period. The hypothesis is that after those five days, the drug pressure from Paxlovid is gone and whatever remnants of the virus are still present are able to cause symptoms again,” Adalja says. “We don’t quite understand why it happens in some people and not others, but it likely has to do with the nuance of the immune response and how that's impacted by antivirals.”\n\nThe risk of rebound [should not preclude someone who's at high risk or severe disease from taking Paxlovid](https:\/\/publichealth.jhu.edu\/2024\/why-more-people-should-be-prescribed-paxlovid-for-covid), and it definitely shouldn’t preclude doctors from prescribing it. “Taking Paxlovid clearly reduces the likelihood of an individual developing severe COVID, irrespective of COVID rebound,” Pekosz emphasizes.\n\n##### **Can COVID rebound happen to people who don’t take Paxlovid?**\nYes. In fall 2020 and spring 2021—before Paxlovid became available—Pekosz and other virologists studied [how infectiousness and viral load varied among individuals](https:\/\/www.nature.com\/articles\/s41564-022-01105-z \"(opens in a new window)\") over the course of a COVID infection. Their results showed [numerous instances of what we now describe as COVID rebound](https:\/\/www.nature.com\/articles\/s41564-022-01105-z\/figures\/1 \"(opens in a new window)\"): a return of symptoms or positive antigen test.\n\nThese results weren’t unexpected, according to Pekosz. “Many of us virologists assumed \\[rebound\\] was happening because we understand that these viruses come and go, they're not smooth curves in terms of your responses,” he says.\n\n##### **Is a person contagious while they have rebound symptoms?**\nPossibly—but Adalja explains that contagiousness is better determined by test positivity than symptoms. “If a person experiences rebound symptoms but doesn’t test positive on a home antigen test, they likely aren’t shedding enough virus to be infectious,” he says. “However, if they test positive on a home antigen test, that does likely correlate with contagiousness.”\n\n##### **When someone tests positive on a home antigen test, does the darkness of the test line correlate to contagiousness?**\nA faint line on a home antigen test is still a positive test result. “The tests are validated to tell you yes or no” to whether it detects viral material, Pekosz explains, not how contagious you are. “A dark line does mean more viral load,” he says, but there’s no system that correlates different shades of red with level of contagiousness.\n\n“If you're testing positive following a previous negative test or following a full course of Paxlovid, that's where masking and distancing becomes important,” Pekosz says. “But again, only at the tail end of an infection, when you’re feeling better and symptoms aren’t severe.”\n\n##### **Does rebound happen with other viruses, like flu and RSV?**\nIt’s likely that rebound occurs with other viral infections, Pekosz explains. “It probably happens with influenza, but we don't have the at-home tests to capture that,” Pekosz says, adding that he hopes future availability of at-home flu tests will allow virologists to analyze flu cases like they have with COVID.\n\n“What we can do in terms of diagnosing ourselves with COVID and following the course of the disease is light-years ahead of what we can do for influenza,” Pekosz says. “It’s a testament to the fact that we've done good science and gotten these tools in place to see these kinds of variations that we've never been able to see with other viruses or infections.”\n\n*Aliza Rosen is a digital content strategist in the Office of External Affairs at the Johns Hopkins Bloomberg School of Public Health.*\n\n## **RELATED:**\n- [More Americans Could Benefit from Paxlovid for COVID Infection](https:\/\/publichealth.jhu.edu\/2024\/why-more-people-should-be-prescribed-paxlovid-for-covid)\n- [What to Know About JN.1, the Latest Omicron Variant](https:\/\/publichealth.jhu.edu\/2024\/jn1-the-dominant-variant-in-the-covid-surge)\n\n## More from the Bloomberg School\n- [See latest headlines](https:\/\/publichealth.jhu.edu\/headlines)\n- Learn more about our departments:\n  - [Environmental Health and Engineering](https:\/\/publichealth.jhu.edu\/departments\/environmental-health-and-engineering)\n  - [Molecular Microbiology and Immunology](https:\/\/publichealth.jhu.edu\/departments\/molecular-microbiology-and-immunology)\n\n## Related Content\n[![A patient fills out a form while her blood and saliva are screened for Hepatitis C and HIV in Spencer, West Virginia, on September 28, 2017.](https:\/\/publichealth.jhu.edu\/sites\/default\/files\/styles\/related_content\/public\/2026-04\/hep-c.jpg?h=4f4378cb&itok=zR0m9KTH)](https:\/\/publichealth.jhu.edu\/2026\/what-to-know-about-hepatitis-c)\n\n### [What to Know About Hepatitis C](https:\/\/publichealth.jhu.edu\/2026\/what-to-know-about-hepatitis-c)\nApril 10, 2026\n\n[![Image of a white van with the Check It logo](https:\/\/publichealth.jhu.edu\/sites\/default\/files\/styles\/related_content\/public\/2026-04\/Check-It-van.jpg?h=96a96008&itok=wrnq2VNV)](https:\/\/publichealth.jhu.edu\/2026\/check-it-drug-checking-program-will-support-baltimore-citys-overdose-response-efforts)\n\n### [Check It Drug Checking Program Will Support Baltimore City’s Overdose Response Efforts](https:\/\/publichealth.jhu.edu\/2026\/check-it-drug-checking-program-will-support-baltimore-citys-overdose-response-efforts)\nApril 09, 2026\n\n### [Why Review of the U.S.’s Measles Elimination Status Has Been Delayed](https:\/\/publichealth.jhu.edu\/2026\/why-review-of-the-uss-measles-elimination-status-has-been-delayed)\nApril 09, 2026\n\n[![man's feet on scale](https:\/\/publichealth.jhu.edu\/sites\/default\/files\/styles\/related_content\/public\/2026-02\/GettyImages-2220445333-3.2-release-scale-weight-loss-glp-1.jpg?h=f321a05b&itok=8b785v-1)](https:\/\/publichealth.jhu.edu\/2026\/glp-1-weight-loss-drugs-comparably-effective-for-patients-across-age-race-and-starting-weight)\n\n### [GLP-1 Weight-Loss Drugs Comparably Effective for Patients Across Age, Race, and Starting Weight](https:\/\/publichealth.jhu.edu\/2026\/glp-1-weight-loss-drugs-comparably-effective-for-patients-across-age-race-and-starting-weight)\nMarch 02, 2026\n\n[![Veterinarian seated in front of client with small dog on her lap lets dog sniff his hand while he speaks to the client.](https:\/\/publichealth.jhu.edu\/sites\/default\/files\/styles\/related_content\/public\/2026-02\/pet-vaccines-veterinarian.jpg?h=f321a05b&itok=pykOpVbz)](https:\/\/publichealth.jhu.edu\/2026\/vaccinating-your-dog-or-cat-can-also-protect-you)\n\n### [Why We Vaccinate Our Dogs and Cats](https:\/\/publichealth.jhu.edu\/2026\/vaccinating-your-dog-or-cat-can-also-protect-you)\nFebruary 27, 2026\n\n**Johns Hopkins Bloomberg School of Public Health**  \n [615 N. Wolfe Street, Baltimore, MD 21205](https:\/\/goo.gl\/maps\/p6Eowe2n6W2FuJ3k7 \"(opens in a new window)\")\n\n## Footer social\n- [LinkedIn](https:\/\/www.linkedin.com\/school\/johns-hopkins-bloomberg-school-of-public-health\/ \"(opens in a new window)\")\n- [Facebook](https:\/\/www.facebook.com\/JohnsHopkinsSPH \"(opens in a new window)\")\n- [Instagram](https:\/\/www.instagram.com\/johnshopkinssph\/ \"(opens in a new window)\")\n- [BlueSky](https:\/\/bsky.app\/profile\/johnshopkinssph.bsky.social \"(opens in a new window)\")\n- [X (Formerly Twitter)](https:\/\/twitter.com\/JohnsHopkinsSPH \"(opens in a new window)\")\n- [Youtube](https:\/\/www.youtube.com\/user\/JohnsHopkinsSPH \"(opens in a new window)\")\n\n## Footer menu primary\n- [Offices & Services](https:\/\/publichealth.jhu.edu\/offices-and-services)\n- [Alumni](https:\/\/publichealth.jhu.edu\/alumni)\n- [Giving](https:\/\/publichealth.jhu.edu\/giving)\n- [Calendars](https:\/\/publichealth.jhu.edu\/calendars-at-the-bloomberg-school)\n- [Careers](https:\/\/publichealth.jhu.edu\/careers \"Job Opportunities and Career Resources\")\n- [Contact Us](https:\/\/publichealth.jhu.edu\/contact-us)\n\n## Footer menu secondary\n- [Centers & Institutes Directory](https:\/\/publichealth.jhu.edu\/centers-and-institutes-directory)\n- [My.PublicHealth](https:\/\/my.publichealth.jhu.edu\/)\n- [My.JH](https:\/\/my.jh.edu\/myJH\/ \"(opens in a new window)\")\n- [CoursePlus](https:\/\/courseplus.jhu.edu\/)\n- [Student Information System](https:\/\/sis.jhu.edu\/)\n\n[Johns Hopkins University](https:\/\/www.jhu.edu\/)\n\n## Footer menu extra\n- [Web Policies](https:\/\/publichealth.jhu.edu\/web-policies)\n- [Accessibility](https:\/\/accessibility.jhu.edu\/)\n- [Website Help](https:\/\/webhelp.publichealth.jhu.edu\/support\/tickets\/new)\n\n## We use cookies on this site to enhance your user experience.\nBy clicking the Accept button, you agree to us doing so.\n\nLearn more\n\nAccept\n\nNo, thanks","attrs_readable_markdown":"What initially was referred to as “Paxlovid rebound”—a return of COVID symptoms or test positivity after starting a course of the antiviral—is now more accurately referred to as “COVID rebound,” because rebound can happen regardless of whether someone takes antivirals.\n\nWhat’s more, it’s likely not a phenomenon unique to COVID, says virologist [Andy Pekosz](https:\/\/publichealth.jhu.edu\/faculty\/1972\/andrew-stanley-pekosz), PhD, a professor in [Molecular Microbiology and Immunology](https:\/\/publichealth.jhu.edu\/departments\/molecular-microbiology-and-immunology). What *is* unique to COVID is the technology—specifically rapid antigen tests—that allows us to track the progress of an infection so closely.\n\nResearchers are continuing to investigate why some people experience COVID rebound, whether people are contagious during this period, and the role antivirals like Paxlovid might play. But one thing is certain, says [Amesh Adalja](https:\/\/publichealth.jhu.edu\/faculty\/3528\/amesh-adalja), MD, a senior scholar at the [Johns Hopkins Center for Health Security](https:\/\/www.centerforhealthsecurity.org\/ \"(opens in a new window)\") who specializes in infectious diseases and pandemic preparedness: The possibility that someone might experience mild rebound symptoms should not deter them from taking Paxlovid if they are at a higher risk for severe illness.\n\n##### **What is COVID rebound?**\nCOVID rebound is “typically described as a recurrence of signs or symptoms or a new positive viral test result after initial recovery from COVID-19,” [according to the CDC](https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7251a1.htm \"(opens in a new window)\"). The order of events generally looks like this: A person is infected with and has symptoms of COVID; their symptoms subside over the course of the infection, and they test negative for COVID on a home antigen test; their symptoms return, and they may test positive again on a home antigen test.\n\nRebound symptoms are generally mild, and no hospitalizations or deaths have occurred as a result of rebound, according to a [December 2023 CDC report](https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7251a1.htm \"(opens in a new window)\").\n\n##### **Why do some people experience COVID rebound?**\nResearchers are still working to understand why rebound happens and how it varies from person to person—with some experiencing a return of symptoms and others only seeing evidence through antigen testing. But at a molecular level, the fact that rebound occurs is not surprising, says Andy Pekosz.\n\n“We think about an infection as starting as nothing, going up to a peak, and then going away, but in reality, your body is much more complicated than that,” he says. Using more sensitive tools, virologists have seen that the amount of virus present in someone with COVID goes up and down over the course of an infection, causing different degrees of symptoms.\n\n##### **Does Paxlovid cause rebound symptoms?**\n[A CDC review of COVID rebound studies](https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7251a1.htm \"(opens in a new window)\") found “no consistent association between treatment and rebound.” Paxlovid does not directly *cause* symptoms to return; in fact, only about [1 in 5 people who take Paxlovid experience rebound](https:\/\/www.acpjournals.org\/doi\/10.7326\/M23-1756 \"(opens in a new window)\"), and many of those are asymptomatic.\n\n“Paxlovid is taken daily for five days, and it’s possible that the immune response is somewhat blunted during that period. The hypothesis is that after those five days, the drug pressure from Paxlovid is gone and whatever remnants of the virus are still present are able to cause symptoms again,” Adalja says. “We don’t quite understand why it happens in some people and not others, but it likely has to do with the nuance of the immune response and how that's impacted by antivirals.”\n\nThe risk of rebound [should not preclude someone who's at high risk or severe disease from taking Paxlovid](https:\/\/publichealth.jhu.edu\/2024\/why-more-people-should-be-prescribed-paxlovid-for-covid), and it definitely shouldn’t preclude doctors from prescribing it. “Taking Paxlovid clearly reduces the likelihood of an individual developing severe COVID, irrespective of COVID rebound,” Pekosz emphasizes.\n\n##### **Can COVID rebound happen to people who don’t take Paxlovid?**\nYes. In fall 2020 and spring 2021—before Paxlovid became available—Pekosz and other virologists studied [how infectiousness and viral load varied among individuals](https:\/\/www.nature.com\/articles\/s41564-022-01105-z \"(opens in a new window)\") over the course of a COVID infection. Their results showed [numerous instances of what we now describe as COVID rebound](https:\/\/www.nature.com\/articles\/s41564-022-01105-z\/figures\/1 \"(opens in a new window)\"): a return of symptoms or positive antigen test.\n\nThese results weren’t unexpected, according to Pekosz. “Many of us virologists assumed \\[rebound\\] was happening because we understand that these viruses come and go, they're not smooth curves in terms of your responses,” he says.\n\n##### **Is a person contagious while they have rebound symptoms?**\nPossibly—but Adalja explains that contagiousness is better determined by test positivity than symptoms. “If a person experiences rebound symptoms but doesn’t test positive on a home antigen test, they likely aren’t shedding enough virus to be infectious,” he says. “However, if they test positive on a home antigen test, that does likely correlate with contagiousness.”\n\n##### **When someone tests positive on a home antigen test, does the darkness of the test line correlate to contagiousness?**\nA faint line on a home antigen test is still a positive test result. “The tests are validated to tell you yes or no” to whether it detects viral material, Pekosz explains, not how contagious you are. “A dark line does mean more viral load,” he says, but there’s no system that correlates different shades of red with level of contagiousness.\n\n“If you're testing positive following a previous negative test or following a full course of Paxlovid, that's where masking and distancing becomes important,” Pekosz says. “But again, only at the tail end of an infection, when you’re feeling better and symptoms aren’t severe.”\n\n##### **Does rebound happen with other viruses, like flu and RSV?**\nIt’s likely that rebound occurs with other viral infections, Pekosz explains. “It probably happens with influenza, but we don't have the at-home tests to capture that,” Pekosz says, adding that he hopes future availability of at-home flu tests will allow virologists to analyze flu cases like they have with COVID.\n\n“What we can do in terms of diagnosing ourselves with COVID and following the course of the disease is light-years ahead of what we can do for influenza,” Pekosz says. “It’s a testament to the fact that we've done good science and gotten these tools in place to see these kinds of variations that we've never been able to see with other viruses or infections.”\n\n*Aliza Rosen is a digital content strategist in the Office of External Affairs at the Johns Hopkins Bloomberg School of Public Health.*\n\n## **RELATED:**\n- [More Americans Could Benefit from Paxlovid for COVID Infection](https:\/\/publichealth.jhu.edu\/2024\/why-more-people-should-be-prescribed-paxlovid-for-covid)\n- [What to Know About JN.1, the Latest Omicron Variant](https:\/\/publichealth.jhu.edu\/2024\/jn1-the-dominant-variant-in-the-covid-surge)","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

5 days ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0.2 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound
Last Crawled	2026-04-10 17:32:08 (5 days ago)
First Indexed	2024-02-21 08:41:26 (2 years ago)
HTTP Status Code	200
Meta Title	What to Know About COVID Rebound \| Johns Hopkins \| Bloomberg School of Public Health
Meta Description	Some people recover from COVID only to have their symptoms return a few days later. That doesn’t surprise virologists.
Meta Canonical	null
Boilerpipe Text	What initially was referred to as “Paxlovid rebound”—a return of COVID symptoms or test positivity after starting a course of the antiviral—is now more accurately referred to as “COVID rebound,” because rebound can happen regardless of whether someone takes antivirals. What’s more, it’s likely not a phenomenon unique to COVID, says virologist Andy Pekosz , PhD, a professor in Molecular Microbiology and Immunology . What is unique to COVID is the technology—specifically rapid antigen tests—that allows us to track the progress of an infection so closely. Researchers are continuing to investigate why some people experience COVID rebound, whether people are contagious during this period, and the role antivirals like Paxlovid might play. But one thing is certain, says Amesh Adalja , MD, a senior scholar at the Johns Hopkins Center for Health Security (link is external) who specializes in infectious diseases and pandemic preparedness: The possibility that someone might experience mild rebound symptoms should not deter them from taking Paxlovid if they are at a higher risk for severe illness. What is COVID rebound? COVID rebound is “typically described as a recurrence of signs or symptoms or a new positive viral test result after initial recovery from COVID-19,” according to the CDC (link is external) . The order of events generally looks like this: A person is infected with and has symptoms of COVID; their symptoms subside over the course of the infection, and they test negative for COVID on a home antigen test; their symptoms return, and they may test positive again on a home antigen test. Rebound symptoms are generally mild, and no hospitalizations or deaths have occurred as a result of rebound, according to a December 2023 CDC report (link is external) . Why do some people experience COVID rebound? Researchers are still working to understand why rebound happens and how it varies from person to person—with some experiencing a return of symptoms and others only seeing evidence through antigen testing. But at a molecular level, the fact that rebound occurs is not surprising, says Andy Pekosz. “We think about an infection as starting as nothing, going up to a peak, and then going away, but in reality, your body is much more complicated than that,” he says. Using more sensitive tools, virologists have seen that the amount of virus present in someone with COVID goes up and down over the course of an infection, causing different degrees of symptoms. Does Paxlovid cause rebound symptoms? A CDC review of COVID rebound studies (link is external) found “no consistent association between treatment and rebound.” Paxlovid does not directly cause symptoms to return; in fact, only about 1 in 5 people who take Paxlovid experience rebound (link is external) , and many of those are asymptomatic. “Paxlovid is taken daily for five days, and it’s possible that the immune response is somewhat blunted during that period. The hypothesis is that after those five days, the drug pressure from Paxlovid is gone and whatever remnants of the virus are still present are able to cause symptoms again,” Adalja says. “We don’t quite understand why it happens in some people and not others, but it likely has to do with the nuance of the immune response and how that's impacted by antivirals.” The risk of rebound should not preclude someone who's at high risk or severe disease from taking Paxlovid , and it definitely shouldn’t preclude doctors from prescribing it. “Taking Paxlovid clearly reduces the likelihood of an individual developing severe COVID, irrespective of COVID rebound,” Pekosz emphasizes. Can COVID rebound happen to people who don’t take Paxlovid? Yes. In fall 2020 and spring 2021—before Paxlovid became available—Pekosz and other virologists studied how infectiousness and viral load varied among individuals (link is external) over the course of a COVID infection. Their results showed numerous instances of what we now describe as COVID rebound (link is external) : a return of symptoms or positive antigen test. These results weren’t unexpected, according to Pekosz. “Many of us virologists assumed [rebound] was happening because we understand that these viruses come and go, they're not smooth curves in terms of your responses,” he says. Is a person contagious while they have rebound symptoms? Possibly—but Adalja explains that contagiousness is better determined by test positivity than symptoms. “If a person experiences rebound symptoms but doesn’t test positive on a home antigen test, they likely aren’t shedding enough virus to be infectious,” he says. “However, if they test positive on a home antigen test, that does likely correlate with contagiousness.” When someone tests positive on a home antigen test, does the darkness of the test line correlate to contagiousness? A faint line on a home antigen test is still a positive test result. “The tests are validated to tell you yes or no” to whether it detects viral material, Pekosz explains, not how contagious you are. “A dark line does mean more viral load,” he says, but there’s no system that correlates different shades of red with level of contagiousness. “If you're testing positive following a previous negative test or following a full course of Paxlovid, that's where masking and distancing becomes important,” Pekosz says. “But again, only at the tail end of an infection, when you’re feeling better and symptoms aren’t severe.” Does rebound happen with other viruses, like flu and RSV? It’s likely that rebound occurs with other viral infections, Pekosz explains. “It probably happens with influenza, but we don't have the at-home tests to capture that,” Pekosz says, adding that he hopes future availability of at-home flu tests will allow virologists to analyze flu cases like they have with COVID. “What we can do in terms of diagnosing ourselves with COVID and following the course of the disease is light-years ahead of what we can do for influenza,” Pekosz says. “It’s a testament to the fact that we've done good science and gotten these tools in place to see these kinds of variations that we've never been able to see with other viruses or infections.” Aliza Rosen is a digital content strategist in the Office of External Affairs at the Johns Hopkins Bloomberg School of Public Health. RELATED: More Americans Could Benefit from Paxlovid for COVID Infection What to Know About JN.1, the Latest Omicron Variant
Markdown	[Johns Hopkins UniversityEst. 1876 America’s First Research University](https://150.jhu.edu/) [Skip to main content](https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound#main-content) - [Expand](https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound) [Departments](https://publichealth.jhu.edu/departments) - [Biochemistry and Molecular Biology](https://publichealth.jhu.edu/departments/biochemistry-and-molecular-biology) - [Biostatistics](https://publichealth.jhu.edu/departments/biostatistics) - [Environmental Health and Engineering](https://publichealth.jhu.edu/departments/environmental-health-and-engineering) - [Epidemiology](https://publichealth.jhu.edu/departments/epidemiology) - [Health Policy and Management](https://publichealth.jhu.edu/departments/health-policy-and-management) - [Health, Behavior and Society](https://publichealth.jhu.edu/departments/health-behavior-and-society) - [International Health](https://publichealth.jhu.edu/departments/international-health) - [Mental Health](https://publichealth.jhu.edu/departments/mental-health) - [Molecular Microbiology and Immunology](https://publichealth.jhu.edu/departments/molecular-microbiology-and-immunology) - [Population, Family and Reproductive Health](https://publichealth.jhu.edu/departments/population-family-and-reproductive-health) - [Faculty](https://publichealth.jhu.edu/faculty/directory/list) - [Topics](https://publichealth.jhu.edu/topics) - [Departments »](https://publichealth.jhu.edu/departments) - [Biochemistry and Molecular Biology](https://publichealth.jhu.edu/departments/biochemistry-and-molecular-biology) - [Biostatistics](https://publichealth.jhu.edu/departments/biostatistics) - [Environmental Health and Engineering](https://publichealth.jhu.edu/departments/environmental-health-and-engineering) - [Epidemiology](https://publichealth.jhu.edu/departments/epidemiology) - [Health Policy and Management](https://publichealth.jhu.edu/departments/health-policy-and-management) - [Health, Behavior and Society](https://publichealth.jhu.edu/departments/health-behavior-and-society) - [International Health](https://publichealth.jhu.edu/departments/international-health) - [Mental Health](https://publichealth.jhu.edu/departments/mental-health) - [Molecular Microbiology and Immunology](https://publichealth.jhu.edu/departments/molecular-microbiology-and-immunology) - [Population, Family and Reproductive Health](https://publichealth.jhu.edu/departments/population-family-and-reproductive-health) - [Faculty](https://publichealth.jhu.edu/faculty/directory/list) - [Topics](https://publichealth.jhu.edu/topics) Search [![Home](https://publichealth.jhu.edu/themes/custom/jhsph/images/logo.svg)](https://publichealth.jhu.edu/) Toggle menus - [Expand](https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound) [Academics](https://publichealth.jhu.edu/academics) - [Explore Programs](https://publichealth.jhu.edu/academics/explore-programs) - [Admissions Services](https://publichealth.jhu.edu/offices-and-services/office-of-admissions-services "Admissions Services") - [Course Directory](https://publichealth.jhu.edu/courses) - [Academic Calendar](https://publichealth.jhu.edu/academics/academic-calendar) - [Lecture Series](https://publichealth.jhu.edu/academics/lecture-series) - [Convocation](https://publichealth.jhu.edu/academics/convocation) - [Expand](https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound) [Research](https://publichealth.jhu.edu/researchbsph) - [Strategy and Development](https://publichealth.jhu.edu/researchbsph/strategy-and-development) - [Implementation and Impact](https://publichealth.jhu.edu/researchbsph/implementation-and-impact) - [Integrity and Oversight](https://publichealth.jhu.edu/researchbsph/integrity-and-oversight) - [Expand](https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound) [Practice](https://publichealth.jhu.edu/practice) - [In the School](https://publichealth.jhu.edu/practice/in-the-school) - [In the Field](https://publichealth.jhu.edu/practice/in-the-field) - [In Baltimore](https://publichealth.jhu.edu/practice/in-baltimore) - [Resources for Practitioners](https://publichealth.jhu.edu/practice/resources-for-practitioners) - [Expand](https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound) [Headlines](https://publichealth.jhu.edu/headlines) - [Articles & News Releases](https://publichealth.jhu.edu/headlines/articles-news-releases) - [In The News](https://publichealth.jhu.edu/headlines/in-the-news) - [Newsletter](https://publichealth.jhu.edu/headlines/public-health-insights-newsletter) - [Podcast](https://publichealth.jhu.edu/headlines/public-health-on-call-podcast) - [Magazine](https://magazine.publichealth.jhu.edu/) - [Events](https://publichealth.jhu.edu/events) - [Statements & Announcements](https://publichealth.jhu.edu/headlines/statements-announcements) - [Newsroom](https://publichealth.jhu.edu/headlines/newsroom) - [Expand](https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound) [About](https://publichealth.jhu.edu/about) - [At a Glance](https://publichealth.jhu.edu/about/at-a-glance) - [Leadership](https://publichealth.jhu.edu/about/leadership) - [Student Life](https://publichealth.jhu.edu/about/student-life) - [Campus](https://publichealth.jhu.edu/about/our-campus) - [Baltimore](https://publichealth.jhu.edu/about/our-home-city-of-baltimore) - [Inclusion, Diversity, Anti-Racism, and Equity (IDARE)](https://publichealth.jhu.edu/about/inclusion-diversity-anti-racism-and-equity-idare) - [History](https://publichealth.jhu.edu/about/history) - [What is Public Health?](https://publichealth.jhu.edu/about/what-is-public-health) - [Apply](https://publichealth.jhu.edu/offices-and-services/office-of-admissions-services/how-to-apply) - [Academics](https://publichealth.jhu.edu/academics) - [Explore Programs](https://publichealth.jhu.edu/academics/explore-programs) - [Admissions Services](https://publichealth.jhu.edu/offices-and-services/office-of-admissions-services "Admissions Services") - [Course Directory](https://publichealth.jhu.edu/courses) - [Academic Calendar](https://publichealth.jhu.edu/academics/academic-calendar) - [Lecture Series](https://publichealth.jhu.edu/academics/lecture-series) - [Convocation](https://publichealth.jhu.edu/academics/convocation) - [Research](https://publichealth.jhu.edu/researchbsph) - [Strategy and Development](https://publichealth.jhu.edu/researchbsph/strategy-and-development) - [Implementation and Impact](https://publichealth.jhu.edu/researchbsph/implementation-and-impact) - [Integrity and Oversight](https://publichealth.jhu.edu/researchbsph/integrity-and-oversight) - [Practice](https://publichealth.jhu.edu/practice) - [In the School](https://publichealth.jhu.edu/practice/in-the-school) - [In the Field](https://publichealth.jhu.edu/practice/in-the-field) - [In Baltimore](https://publichealth.jhu.edu/practice/in-baltimore) - [Resources for Practitioners](https://publichealth.jhu.edu/practice/resources-for-practitioners) - [Headlines](https://publichealth.jhu.edu/headlines) - [Articles & News Releases](https://publichealth.jhu.edu/headlines/articles-news-releases) - [In The News](https://publichealth.jhu.edu/headlines/in-the-news) - [Newsletter](https://publichealth.jhu.edu/headlines/public-health-insights-newsletter) - [Podcast](https://publichealth.jhu.edu/headlines/public-health-on-call-podcast) - [Magazine](https://magazine.publichealth.jhu.edu/) - [Events](https://publichealth.jhu.edu/events) - [Statements & Announcements](https://publichealth.jhu.edu/headlines/statements-announcements) - [Newsroom](https://publichealth.jhu.edu/headlines/newsroom) - [About](https://publichealth.jhu.edu/about) - [At a Glance](https://publichealth.jhu.edu/about/at-a-glance) - [Leadership](https://publichealth.jhu.edu/about/leadership) - [Student Life](https://publichealth.jhu.edu/about/student-life) - [Campus](https://publichealth.jhu.edu/about/our-campus) - [Baltimore](https://publichealth.jhu.edu/about/our-home-city-of-baltimore) - [Inclusion, Diversity, Anti-Racism, and Equity (IDARE)](https://publichealth.jhu.edu/about/inclusion-diversity-anti-racism-and-equity-idare) - [History](https://publichealth.jhu.edu/about/history) - [What is Public Health?](https://publichealth.jhu.edu/about/what-is-public-health) - [Apply](https://publichealth.jhu.edu/offices-and-services/office-of-admissions-services/how-to-apply) - [Expand](https://publichealth.jhu.edu/2024/what-to-know-about-covid-rebound) [Departments](https://publichealth.jhu.edu/departments) - [Biochemistry and Molecular Biology](https://publichealth.jhu.edu/departments/biochemistry-and-molecular-biology) - [Biostatistics](https://publichealth.jhu.edu/departments/biostatistics) - [Environmental Health and Engineering](https://publichealth.jhu.edu/departments/environmental-health-and-engineering) - [Epidemiology](https://publichealth.jhu.edu/departments/epidemiology) - [Health Policy and Management](https://publichealth.jhu.edu/departments/health-policy-and-management) - [Health, Behavior and Society](https://publichealth.jhu.edu/departments/health-behavior-and-society) - [International Health](https://publichealth.jhu.edu/departments/international-health) - [Mental Health](https://publichealth.jhu.edu/departments/mental-health) - [Molecular Microbiology and Immunology](https://publichealth.jhu.edu/departments/molecular-microbiology-and-immunology) - [Population, Family and Reproductive Health](https://publichealth.jhu.edu/departments/population-family-and-reproductive-health) - [Faculty](https://publichealth.jhu.edu/faculty/directory/list) - [Topics](https://publichealth.jhu.edu/topics) - [Departments »](https://publichealth.jhu.edu/departments) - [Biochemistry and Molecular Biology](https://publichealth.jhu.edu/departments/biochemistry-and-molecular-biology) - [Biostatistics](https://publichealth.jhu.edu/departments/biostatistics) - [Environmental Health and Engineering](https://publichealth.jhu.edu/departments/environmental-health-and-engineering) - [Epidemiology](https://publichealth.jhu.edu/departments/epidemiology) - [Health Policy and Management](https://publichealth.jhu.edu/departments/health-policy-and-management) - [Health, Behavior and Society](https://publichealth.jhu.edu/departments/health-behavior-and-society) - [International Health](https://publichealth.jhu.edu/departments/international-health) - [Mental Health](https://publichealth.jhu.edu/departments/mental-health) - [Molecular Microbiology and Immunology](https://publichealth.jhu.edu/departments/molecular-microbiology-and-immunology) - [Population, Family and Reproductive Health](https://publichealth.jhu.edu/departments/population-family-and-reproductive-health) - [Faculty](https://publichealth.jhu.edu/faculty/directory/list) - [Topics](https://publichealth.jhu.edu/topics) Search Bloomberg School # COVID Rebound Can Happen Whether or Not You Take Paxlovid How our bodies respond to viral infections is “not a smooth curve” Published February 20, 2024 By Aliza Rosen [COVID-19](https://publichealth.jhu.edu/topics/covid-19-and-public-health) [Drugs](https://publichealth.jhu.edu/topics/drugs-and-public-health) [Infectious Diseases](https://publichealth.jhu.edu/topics/infectious-diseases-and-public-health) ![A woman sits on a couch wrapped in a blanket blowing her nose ](https://publichealth.jhu.edu/sites/default/files/styles/article_feature/public/2024-02/covid-rebound-symptoms.jpg?h=6e972868&itok=vRxA1UF7) What initially was referred to as “Paxlovid rebound”—a return of COVID symptoms or test positivity after starting a course of the antiviral—is now more accurately referred to as “COVID rebound,” because rebound can happen regardless of whether someone takes antivirals. What’s more, it’s likely not a phenomenon unique to COVID, says virologist [Andy Pekosz](https://publichealth.jhu.edu/faculty/1972/andrew-stanley-pekosz), PhD, a professor in [Molecular Microbiology and Immunology](https://publichealth.jhu.edu/departments/molecular-microbiology-and-immunology). What is unique to COVID is the technology—specifically rapid antigen tests—that allows us to track the progress of an infection so closely. Researchers are continuing to investigate why some people experience COVID rebound, whether people are contagious during this period, and the role antivirals like Paxlovid might play. But one thing is certain, says [Amesh Adalja](https://publichealth.jhu.edu/faculty/3528/amesh-adalja), MD, a senior scholar at the [Johns Hopkins Center for Health Security](https://www.centerforhealthsecurity.org/ "(opens in a new window)") who specializes in infectious diseases and pandemic preparedness: The possibility that someone might experience mild rebound symptoms should not deter them from taking Paxlovid if they are at a higher risk for severe illness. ##### What is COVID rebound? COVID rebound is “typically described as a recurrence of signs or symptoms or a new positive viral test result after initial recovery from COVID-19,” [according to the CDC](https://www.cdc.gov/mmwr/volumes/72/wr/mm7251a1.htm "(opens in a new window)"). The order of events generally looks like this: A person is infected with and has symptoms of COVID; their symptoms subside over the course of the infection, and they test negative for COVID on a home antigen test; their symptoms return, and they may test positive again on a home antigen test. Rebound symptoms are generally mild, and no hospitalizations or deaths have occurred as a result of rebound, according to a [December 2023 CDC report](https://www.cdc.gov/mmwr/volumes/72/wr/mm7251a1.htm "(opens in a new window)"). ##### Why do some people experience COVID rebound? Researchers are still working to understand why rebound happens and how it varies from person to person—with some experiencing a return of symptoms and others only seeing evidence through antigen testing. But at a molecular level, the fact that rebound occurs is not surprising, says Andy Pekosz. “We think about an infection as starting as nothing, going up to a peak, and then going away, but in reality, your body is much more complicated than that,” he says. Using more sensitive tools, virologists have seen that the amount of virus present in someone with COVID goes up and down over the course of an infection, causing different degrees of symptoms. ##### Does Paxlovid cause rebound symptoms? [A CDC review of COVID rebound studies](https://www.cdc.gov/mmwr/volumes/72/wr/mm7251a1.htm "(opens in a new window)") found “no consistent association between treatment and rebound.” Paxlovid does not directly cause symptoms to return; in fact, only about [1 in 5 people who take Paxlovid experience rebound](https://www.acpjournals.org/doi/10.7326/M23-1756 "(opens in a new window)"), and many of those are asymptomatic. “Paxlovid is taken daily for five days, and it’s possible that the immune response is somewhat blunted during that period. The hypothesis is that after those five days, the drug pressure from Paxlovid is gone and whatever remnants of the virus are still present are able to cause symptoms again,” Adalja says. “We don’t quite understand why it happens in some people and not others, but it likely has to do with the nuance of the immune response and how that's impacted by antivirals.” The risk of rebound [should not preclude someone who's at high risk or severe disease from taking Paxlovid](https://publichealth.jhu.edu/2024/why-more-people-should-be-prescribed-paxlovid-for-covid), and it definitely shouldn’t preclude doctors from prescribing it. “Taking Paxlovid clearly reduces the likelihood of an individual developing severe COVID, irrespective of COVID rebound,” Pekosz emphasizes. ##### Can COVID rebound happen to people who don’t take Paxlovid? Yes. In fall 2020 and spring 2021—before Paxlovid became available—Pekosz and other virologists studied [how infectiousness and viral load varied among individuals](https://www.nature.com/articles/s41564-022-01105-z "(opens in a new window)") over the course of a COVID infection. Their results showed [numerous instances of what we now describe as COVID rebound](https://www.nature.com/articles/s41564-022-01105-z/figures/1 "(opens in a new window)"): a return of symptoms or positive antigen test. These results weren’t unexpected, according to Pekosz. “Many of us virologists assumed \[rebound\] was happening because we understand that these viruses come and go, they're not smooth curves in terms of your responses,” he says. ##### Is a person contagious while they have rebound symptoms? Possibly—but Adalja explains that contagiousness is better determined by test positivity than symptoms. “If a person experiences rebound symptoms but doesn’t test positive on a home antigen test, they likely aren’t shedding enough virus to be infectious,” he says. “However, if they test positive on a home antigen test, that does likely correlate with contagiousness.” ##### When someone tests positive on a home antigen test, does the darkness of the test line correlate to contagiousness? A faint line on a home antigen test is still a positive test result. “The tests are validated to tell you yes or no” to whether it detects viral material, Pekosz explains, not how contagious you are. “A dark line does mean more viral load,” he says, but there’s no system that correlates different shades of red with level of contagiousness. “If you're testing positive following a previous negative test or following a full course of Paxlovid, that's where masking and distancing becomes important,” Pekosz says. “But again, only at the tail end of an infection, when you’re feeling better and symptoms aren’t severe.” ##### Does rebound happen with other viruses, like flu and RSV? It’s likely that rebound occurs with other viral infections, Pekosz explains. “It probably happens with influenza, but we don't have the at-home tests to capture that,” Pekosz says, adding that he hopes future availability of at-home flu tests will allow virologists to analyze flu cases like they have with COVID. “What we can do in terms of diagnosing ourselves with COVID and following the course of the disease is light-years ahead of what we can do for influenza,” Pekosz says. “It’s a testament to the fact that we've done good science and gotten these tools in place to see these kinds of variations that we've never been able to see with other viruses or infections.” Aliza Rosen is a digital content strategist in the Office of External Affairs at the Johns Hopkins Bloomberg School of Public Health. ## RELATED: - [More Americans Could Benefit from Paxlovid for COVID Infection](https://publichealth.jhu.edu/2024/why-more-people-should-be-prescribed-paxlovid-for-covid) - [What to Know About JN.1, the Latest Omicron Variant](https://publichealth.jhu.edu/2024/jn1-the-dominant-variant-in-the-covid-surge) ## More from the Bloomberg School - [See latest headlines](https://publichealth.jhu.edu/headlines) - Learn more about our departments: - [Environmental Health and Engineering](https://publichealth.jhu.edu/departments/environmental-health-and-engineering) - [Molecular Microbiology and Immunology](https://publichealth.jhu.edu/departments/molecular-microbiology-and-immunology) ## Related Content [![A patient fills out a form while her blood and saliva are screened for Hepatitis C and HIV in Spencer, West Virginia, on September 28, 2017.](https://publichealth.jhu.edu/sites/default/files/styles/related_content/public/2026-04/hep-c.jpg?h=4f4378cb&itok=zR0m9KTH)](https://publichealth.jhu.edu/2026/what-to-know-about-hepatitis-c) ### [What to Know About Hepatitis C](https://publichealth.jhu.edu/2026/what-to-know-about-hepatitis-c) April 10, 2026 [![Image of a white van with the Check It logo](https://publichealth.jhu.edu/sites/default/files/styles/related_content/public/2026-04/Check-It-van.jpg?h=96a96008&itok=wrnq2VNV)](https://publichealth.jhu.edu/2026/check-it-drug-checking-program-will-support-baltimore-citys-overdose-response-efforts) ### [Check It Drug Checking Program Will Support Baltimore City’s Overdose Response Efforts](https://publichealth.jhu.edu/2026/check-it-drug-checking-program-will-support-baltimore-citys-overdose-response-efforts) April 09, 2026 ### [Why Review of the U.S.’s Measles Elimination Status Has Been Delayed](https://publichealth.jhu.edu/2026/why-review-of-the-uss-measles-elimination-status-has-been-delayed) April 09, 2026 [![man's feet on scale](https://publichealth.jhu.edu/sites/default/files/styles/related_content/public/2026-02/GettyImages-2220445333-3.2-release-scale-weight-loss-glp-1.jpg?h=f321a05b&itok=8b785v-1)](https://publichealth.jhu.edu/2026/glp-1-weight-loss-drugs-comparably-effective-for-patients-across-age-race-and-starting-weight) ### [GLP-1 Weight-Loss Drugs Comparably Effective for Patients Across Age, Race, and Starting Weight](https://publichealth.jhu.edu/2026/glp-1-weight-loss-drugs-comparably-effective-for-patients-across-age-race-and-starting-weight) March 02, 2026 [![Veterinarian seated in front of client with small dog on her lap lets dog sniff his hand while he speaks to the client.](https://publichealth.jhu.edu/sites/default/files/styles/related_content/public/2026-02/pet-vaccines-veterinarian.jpg?h=f321a05b&itok=pykOpVbz)](https://publichealth.jhu.edu/2026/vaccinating-your-dog-or-cat-can-also-protect-you) ### [Why We Vaccinate Our Dogs and Cats](https://publichealth.jhu.edu/2026/vaccinating-your-dog-or-cat-can-also-protect-you) February 27, 2026 Johns Hopkins Bloomberg School of Public Health [615 N. Wolfe Street, Baltimore, MD 21205](https://goo.gl/maps/p6Eowe2n6W2FuJ3k7 "(opens in a new window)") ## Footer social - [LinkedIn](https://www.linkedin.com/school/johns-hopkins-bloomberg-school-of-public-health/ "(opens in a new window)") - [Facebook](https://www.facebook.com/JohnsHopkinsSPH "(opens in a new window)") - [Instagram](https://www.instagram.com/johnshopkinssph/ "(opens in a new window)") - [BlueSky](https://bsky.app/profile/johnshopkinssph.bsky.social "(opens in a new window)") - [X (Formerly Twitter)](https://twitter.com/JohnsHopkinsSPH "(opens in a new window)") - [Youtube](https://www.youtube.com/user/JohnsHopkinsSPH "(opens in a new window)") ## Footer menu primary - [Offices & Services](https://publichealth.jhu.edu/offices-and-services) - [Alumni](https://publichealth.jhu.edu/alumni) - [Giving](https://publichealth.jhu.edu/giving) - [Calendars](https://publichealth.jhu.edu/calendars-at-the-bloomberg-school) - [Careers](https://publichealth.jhu.edu/careers "Job Opportunities and Career Resources") - [Contact Us](https://publichealth.jhu.edu/contact-us) ## Footer menu secondary - [Centers & Institutes Directory](https://publichealth.jhu.edu/centers-and-institutes-directory) - [My.PublicHealth](https://my.publichealth.jhu.edu/) - [My.JH](https://my.jh.edu/myJH/ "(opens in a new window)") - [CoursePlus](https://courseplus.jhu.edu/) - [Student Information System](https://sis.jhu.edu/) [Johns Hopkins University](https://www.jhu.edu/) ## Footer menu extra - [Web Policies](https://publichealth.jhu.edu/web-policies) - [Accessibility](https://accessibility.jhu.edu/) - [Website Help](https://webhelp.publichealth.jhu.edu/support/tickets/new) ## We use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so. Learn more Accept No, thanks
Readable Markdown	What initially was referred to as “Paxlovid rebound”—a return of COVID symptoms or test positivity after starting a course of the antiviral—is now more accurately referred to as “COVID rebound,” because rebound can happen regardless of whether someone takes antivirals. What’s more, it’s likely not a phenomenon unique to COVID, says virologist [Andy Pekosz](https://publichealth.jhu.edu/faculty/1972/andrew-stanley-pekosz), PhD, a professor in [Molecular Microbiology and Immunology](https://publichealth.jhu.edu/departments/molecular-microbiology-and-immunology). What is unique to COVID is the technology—specifically rapid antigen tests—that allows us to track the progress of an infection so closely. Researchers are continuing to investigate why some people experience COVID rebound, whether people are contagious during this period, and the role antivirals like Paxlovid might play. But one thing is certain, says [Amesh Adalja](https://publichealth.jhu.edu/faculty/3528/amesh-adalja), MD, a senior scholar at the [Johns Hopkins Center for Health Security](https://www.centerforhealthsecurity.org/ "(opens in a new window)") who specializes in infectious diseases and pandemic preparedness: The possibility that someone might experience mild rebound symptoms should not deter them from taking Paxlovid if they are at a higher risk for severe illness. ##### What is COVID rebound? COVID rebound is “typically described as a recurrence of signs or symptoms or a new positive viral test result after initial recovery from COVID-19,” [according to the CDC](https://www.cdc.gov/mmwr/volumes/72/wr/mm7251a1.htm "(opens in a new window)"). The order of events generally looks like this: A person is infected with and has symptoms of COVID; their symptoms subside over the course of the infection, and they test negative for COVID on a home antigen test; their symptoms return, and they may test positive again on a home antigen test. Rebound symptoms are generally mild, and no hospitalizations or deaths have occurred as a result of rebound, according to a [December 2023 CDC report](https://www.cdc.gov/mmwr/volumes/72/wr/mm7251a1.htm "(opens in a new window)"). ##### Why do some people experience COVID rebound? Researchers are still working to understand why rebound happens and how it varies from person to person—with some experiencing a return of symptoms and others only seeing evidence through antigen testing. But at a molecular level, the fact that rebound occurs is not surprising, says Andy Pekosz. “We think about an infection as starting as nothing, going up to a peak, and then going away, but in reality, your body is much more complicated than that,” he says. Using more sensitive tools, virologists have seen that the amount of virus present in someone with COVID goes up and down over the course of an infection, causing different degrees of symptoms. ##### Does Paxlovid cause rebound symptoms? [A CDC review of COVID rebound studies](https://www.cdc.gov/mmwr/volumes/72/wr/mm7251a1.htm "(opens in a new window)") found “no consistent association between treatment and rebound.” Paxlovid does not directly cause symptoms to return; in fact, only about [1 in 5 people who take Paxlovid experience rebound](https://www.acpjournals.org/doi/10.7326/M23-1756 "(opens in a new window)"), and many of those are asymptomatic. “Paxlovid is taken daily for five days, and it’s possible that the immune response is somewhat blunted during that period. The hypothesis is that after those five days, the drug pressure from Paxlovid is gone and whatever remnants of the virus are still present are able to cause symptoms again,” Adalja says. “We don’t quite understand why it happens in some people and not others, but it likely has to do with the nuance of the immune response and how that's impacted by antivirals.” The risk of rebound [should not preclude someone who's at high risk or severe disease from taking Paxlovid](https://publichealth.jhu.edu/2024/why-more-people-should-be-prescribed-paxlovid-for-covid), and it definitely shouldn’t preclude doctors from prescribing it. “Taking Paxlovid clearly reduces the likelihood of an individual developing severe COVID, irrespective of COVID rebound,” Pekosz emphasizes. ##### Can COVID rebound happen to people who don’t take Paxlovid? Yes. In fall 2020 and spring 2021—before Paxlovid became available—Pekosz and other virologists studied [how infectiousness and viral load varied among individuals](https://www.nature.com/articles/s41564-022-01105-z "(opens in a new window)") over the course of a COVID infection. Their results showed [numerous instances of what we now describe as COVID rebound](https://www.nature.com/articles/s41564-022-01105-z/figures/1 "(opens in a new window)"): a return of symptoms or positive antigen test. These results weren’t unexpected, according to Pekosz. “Many of us virologists assumed \[rebound\] was happening because we understand that these viruses come and go, they're not smooth curves in terms of your responses,” he says. ##### Is a person contagious while they have rebound symptoms? Possibly—but Adalja explains that contagiousness is better determined by test positivity than symptoms. “If a person experiences rebound symptoms but doesn’t test positive on a home antigen test, they likely aren’t shedding enough virus to be infectious,” he says. “However, if they test positive on a home antigen test, that does likely correlate with contagiousness.” ##### When someone tests positive on a home antigen test, does the darkness of the test line correlate to contagiousness? A faint line on a home antigen test is still a positive test result. “The tests are validated to tell you yes or no” to whether it detects viral material, Pekosz explains, not how contagious you are. “A dark line does mean more viral load,” he says, but there’s no system that correlates different shades of red with level of contagiousness. “If you're testing positive following a previous negative test or following a full course of Paxlovid, that's where masking and distancing becomes important,” Pekosz says. “But again, only at the tail end of an infection, when you’re feeling better and symptoms aren’t severe.” ##### Does rebound happen with other viruses, like flu and RSV? It’s likely that rebound occurs with other viral infections, Pekosz explains. “It probably happens with influenza, but we don't have the at-home tests to capture that,” Pekosz says, adding that he hopes future availability of at-home flu tests will allow virologists to analyze flu cases like they have with COVID. “What we can do in terms of diagnosing ourselves with COVID and following the course of the disease is light-years ahead of what we can do for influenza,” Pekosz says. “It’s a testament to the fact that we've done good science and gotten these tools in place to see these kinds of variations that we've never been able to see with other viruses or infections.” Aliza Rosen is a digital content strategist in the Office of External Affairs at the Johns Hopkins Bloomberg School of Public Health. ## RELATED: - [More Americans Could Benefit from Paxlovid for COVID Infection](https://publichealth.jhu.edu/2024/why-more-people-should-be-prescribed-paxlovid-for-covid) - [What to Know About JN.1, the Latest Omicron Variant](https://publichealth.jhu.edu/2024/jn1-the-dominant-variant-in-the-covid-surge)
Shard	179 (laksa)
Root Hash	6599457417117746179
Unparsed URL	edu,jhu!publichealth,/2024/what-to-know-about-covid-rebound s443